New dosing guidelines aim to cut cancer treatment disruptions for duffy null patients
Disease control
Not yet recruiting
This study tests whether using special dosing guidelines for people with the Duffy null blood type can reduce or delay the need to lower or pause their cancer drugs, and lower the risk of fever from low white blood cells. It includes 90 adults with multiple myeloma or triple-nega…
Phase: PHASE1 • Sponsor: Andrew Hantel, MD • Aim: Disease control
Last updated May 17, 2026 03:25 UTC